Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Sep;36(9):1943–1950. doi: 10.1128/aac.36.9.1943

Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.

P D Walzer 1, J Foy 1, P Steele 1, M White 1
PMCID: PMC192213  PMID: 1416885

Abstract

Over a 7-year period, we analyzed 261 dose regimens of antimicrobial drugs in the treatment and prevention of Pneumocystis carinii pneumonia in an immunosuppressed rat model. These compounds ranged from drugs in clinical use to newly synthesized agents. Drug efficacy was expressed as the magnitude of the reduction in median P. carinii cyst or nucleus counts on a scale ranging from inactive (less than 5-fold) to very markedly active (greater than or equal to 1,000-fold). The classification system was reproducible and allowed drugs studied at different times to be compared with each other. The system demonstrated a hierarchy of anti-P. carinii activity not only among classes of compounds but also among individual members of a drug class. Sulfonamides, sulfones, and diamidines were the most active agents; some purine nucleosides and nitrofurans also showed promising activity; and most antiparasitic, antifungal, antibacterial, and antiviral drugs were inactive. We conclude that this classification system represents a simple, quantitative method of comparing the activities of antimicrobial drugs against P. carinii. Information gained from this system should be helpful in developing new anti-P. carinii compounds and establishing standard procedures for their evaluation.

Full text

PDF
1947

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartlett M. S., Queener S. F., Tidwell R. R., Milhous W. K., Berman J. D., Ellis W. Y., Smith J. W. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. Antimicrob Agents Chemother. 1991 Feb;35(2):277–282. doi: 10.1128/aac.35.2.277. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brun-Pascaud M., Fay M., Zhong M., Bauchet J., Dux-Guyot A., Pocidalo J. J. Use of fluoroquinolones for prophylaxis of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992 Feb;36(2):470–472. doi: 10.1128/aac.36.2.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Clarkson A. B., Jr, Sarić M., Grady R. W. Deferoxamine and eflornithine (DL-alpha-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Sep;34(9):1833–1835. doi: 10.1128/aac.34.9.1833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clarkson A. B., Jr, Williams D. E., Rosenberg C. Efficacy of DL-alpha-difluoromethylornithine in a rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Aug;32(8):1158–1163. doi: 10.1128/aac.32.8.1158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cushion M. T., Ruffolo J. J., Walzer P. D. Analysis of the developmental stages of Pneumocystis carinii, in vitro. Lab Invest. 1988 Mar;58(3):324–331. [PubMed] [Google Scholar]
  6. Cushion M. T., Stanforth D., Linke M. J., Walzer P. D. Method of testing the susceptibility of Pneumocystis carinii to antimicrobial agents in vitro. Antimicrob Agents Chemother. 1985 Dec;28(6):796–801. doi: 10.1128/aac.28.6.796. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. D'Antonio R. G., Johnson D. B., Winn R. E., van Dellen A. F., Evans M. E. Effect of folinic acid on the capacity of trimethoprim-sulfamethoxazole to prevent and treat Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother. 1986 Feb;29(2):327–329. doi: 10.1128/aac.29.2.327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Debs R. J., Blumenfeld W., Brunette E. N., Straubinger R. M., Montgomery A. B., Lin E., Agabian N., Papahadjopoulos D. Successful treatment with aerosolized pentamidine of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother. 1987 Jan;31(1):37–41. doi: 10.1128/aac.31.1.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Frenkel J. K., Good J. T., Shultz J. A. Latent Pneumocystis infection of rats, relapse, and chemotherapy. Lab Invest. 1966 Oct;15(10):1559–1577. [PubMed] [Google Scholar]
  10. Gigliotti F., Hughes W. T. Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest. 1988 Jun;81(6):1666–1668. doi: 10.1172/JCI113503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Girard P. M., Brun-Pascaud M., Farinotti R., Tamisier L., Kernbaum S. Pentamidine aerosol in prophylaxis and treatment of murine Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1987 Jul;31(7):978–981. doi: 10.1128/aac.31.7.978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hughes W. T., Gray V. L., Gutteridge W. E., Latter V. S., Pudney M. Efficacy of a hydroxynaphthoquinone, 566C80, in experimental Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1990 Feb;34(2):225–228. doi: 10.1128/aac.34.2.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hughes W. T. Macrolide-antifol synergism in anti-Pneumocystis carinii therapeutics. J Protozool. 1991 Nov-Dec;38(6):160S–160S. [PubMed] [Google Scholar]
  14. Hughes W. T., McNabb P. C., Makres T. D., Feldman S. Efficacy of trimethoprim and sulfamethoxazole in the prevention and treatment of Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1974 Mar;5(3):289–293. doi: 10.1128/aac.5.3.289. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hughes W. T., Smith-McCain B. L. Effects of sulfonylurea compounds on Pneumocystis carinii. J Infect Dis. 1986 May;153(5):944–947. doi: 10.1093/infdis/153.5.944. [DOI] [PubMed] [Google Scholar]
  16. Hughes W. T., Smith B. L. Efficacy of diaminodiphenylsulfone and other drugs in murine Pneumocystis carinii pneumonitis. Antimicrob Agents Chemother. 1984 Oct;26(4):436–440. doi: 10.1128/aac.26.4.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hughes W. T., Smith B. L. Intermittent chemoprophylaxis for Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1983 Aug;24(2):300–301. doi: 10.1128/aac.24.2.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hughes W. T., Smith B. L., Jacobus D. P. Successful treatment and prevention of murine Pneumocystis carinii pneumonitis with 4,4'-sulfonylbisformanilide. Antimicrob Agents Chemother. 1986 Mar;29(3):509–510. doi: 10.1128/aac.29.3.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Hussain Z., Carlson M. L., Craig I. D., Lannigan R. Efficacy of tetroxoprim/sulphadiazine in the treatment of Pneumocystis carinii pneumonitis in rats. J Antimicrob Chemother. 1985 May;15(5):575–578. doi: 10.1093/jac/15.5.575. [DOI] [PubMed] [Google Scholar]
  20. Jones S. K., Hall J. E., Allen M. A., Morrison S. D., Ohemeng K. A., Reddy V. V., Geratz J. D., Tidwell R. R. Novel pentamidine analogs in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1990 Jun;34(6):1026–1030. doi: 10.1128/aac.34.6.1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kim C. K., Foy J. M., Cushion M. T., Stanforth D., Linke M. J., Hendrix H. L., Walzer P. D. Comparison of histologic and quantitative techniques in evaluation of therapy for experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1987 Feb;31(2):197–201. doi: 10.1128/aac.31.2.197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kluge R. M., Spaulding D. M., Spain A. J. Combination of pentamidine and trimethoprim-sulfamethoxazole in therapy of Pneumocystis carinii pneumonia in rats. Antimicrob Agents Chemother. 1978 Jun;13(6):975–978. doi: 10.1128/aac.13.6.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kovacs J. A., Allegra C. J., Kennedy S., Swan J. C., Drake J., Parrillo J. E., Chabner B., Masur H. Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am J Trop Med Hyg. 1988 Nov;39(5):491–496. doi: 10.4269/ajtmh.1988.39.491. [DOI] [PubMed] [Google Scholar]
  24. Marr J. J., Berens R. L., Cohn N. K., Nelson D. J., Klein R. S. Biological action of inosine analogs in Leishmania and Trypanosoma spp. Antimicrob Agents Chemother. 1984 Feb;25(2):292–295. doi: 10.1128/aac.25.2.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Matsumoto Y., Yamada M., Amagai T. Yeast glucan of Pneumocystis carinii cyst wall: an excellent target for chemotherapy. J Protozool. 1991 Nov-Dec;38(6):6S–7S. [PubMed] [Google Scholar]
  26. Queener S. F., Bartlett M. S., Jay M. A., Durkin M. M., Smith J. W. Activity of lipid-soluble inhibitors of dihydrofolate reductase against Pneumocystis carinii in culture and in a rat model of infection. Antimicrob Agents Chemother. 1987 Sep;31(9):1323–1327. doi: 10.1128/aac.31.9.1323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Queener S. F., Bartlett M. S., Richardson J. D., Durkin M. M., Jay M. A., Smith J. W. Activity of clindamycin with primaquine against Pneumocystis carinii in vitro and in vivo. Antimicrob Agents Chemother. 1988 Jun;32(6):807–813. doi: 10.1128/aac.32.6.807. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schmatz D. M., Powles M., McFadden D. C., Pittarelli L. A., Liberator P. A., Anderson J. W. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J Protozool. 1991 Nov-Dec;38(6):151S–153S. [PubMed] [Google Scholar]
  29. Schmatz D. M., Romancheck M. A., Pittarelli L. A., Schwartz R. E., Fromtling R. A., Nollstadt K. H., Vanmiddlesworth F. L., Wilson K. E., Turner M. J. Treatment of Pneumocystis carinii pneumonia with 1,3-beta-glucan synthesis inhibitors. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5950–5954. doi: 10.1073/pnas.87.15.5950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Shear H. L., Valladares G., Narachi M. A. Enhanced treatment of Pneumocystis carinii pneumonia in rats with interferon-gamma and reduced doses of trimethoprim/sulfamethoxazole. J Acquir Immune Defic Syndr. 1990;3(10):943–948. [PubMed] [Google Scholar]
  31. Smith J. W., Bartlett M. S., Queener S. F., Durkin M. M., Jay M. A., Hull M. T., Klein R. S., Marr J. J. Pneumocystis carinii pneumonia therapy with 9-deazainosine in rats. Diagn Microbiol Infect Dis. 1987 Jun;7(2):113–118. doi: 10.1016/0732-8893(87)90028-9. [DOI] [PubMed] [Google Scholar]
  32. Sundberg R. J., Dahlhausen D. J., Manikumar G., Mavunkel B., Biswas A., Srinivasan V., Musallam H. A., Reid W. A., Jr, Ager A. L. Cationic antiprotozoal drugs. Trypanocidal activity of 2-(4'-formylphenyl)imidazo[1,2-a]pyridinium guanylhydrazones and related derivatives of quaternary heteroaromatic compounds. J Med Chem. 1990 Jan;33(1):298–307. doi: 10.1021/jm00163a049. [DOI] [PubMed] [Google Scholar]
  33. Tidwell R. R., Jones S. K., Geratz J. D., Ohemeng K. A., Cory M., Hall J. E. Analogues of 1,5-bis(4-amidinophenoxy)pentane (pentamidine) in the treatment of experimental Pneumocystis carinii pneumonia. J Med Chem. 1990 Apr;33(4):1252–1257. doi: 10.1021/jm00166a026. [DOI] [PubMed] [Google Scholar]
  34. Ulrich P., Cerami A. Trypanocidal 1,3-arylene diketone bis(guanylhydrazone)s. Structure-activity relationships among substituted and heterocyclic analogues. J Med Chem. 1984 Jan;27(1):35–40. doi: 10.1021/jm00367a007. [DOI] [PubMed] [Google Scholar]
  35. Walzer P. D., Foy J., Steele P., Kim C. K., White M., Klein R. S., Otter B. A., Allegra C. Activities of antifolate, antiviral, and other drugs in an immunosuppressed rat model of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1992 Sep;36(9):1935–1942. doi: 10.1128/aac.36.9.1935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Walzer P. D., Kim C. K., Foy J. M., Linke M. J., Cushion M. T. Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jan;32(1):96–103. doi: 10.1128/aac.32.1.96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Walzer P. D., Kim C. K., Foy J., Linke M. J., Cushion M. T. Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1988 Jun;32(6):896–905. doi: 10.1128/aac.32.6.896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Walzer P. D., Kim C. K., Foy J., Zhang J. L. Furazolidone and nitrofurantoin in the treatment of experimental Pneumocystis carinii pneumonia. Antimicrob Agents Chemother. 1991 Jan;35(1):158–163. doi: 10.1128/aac.35.1.158. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Walzer P. D., Powell R. D., Jr, Yoneda K., Rutledge M. E., Milder J. E. Growth characteristics and pathogenesis of experimental Pneumocystis carinii pneumonia. Infect Immun. 1980 Mar;27(3):928–937. doi: 10.1128/iai.27.3.928-937.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES